Career of Diabetes and Medical Pioneer Al Mann Honored at Boston Gala
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Needham Starts NeoVolta (NEOV) at Buy
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
Sanofi (SNY) 'Seemingly Committed' to MannKind's (MNKD) Afrezza, RBC Says; 2nd-Half Efforts to Focus on Awareness
June 9, 2015 12:04 PM EDTRBC Capital analyst Adnan Butt weighed in on MannKind (NASDAQ: MNKD) after partner Sanofi's (NYSE: SNY) update at ADA included Afrezza where it highlighted selling efforts will pick up in second-half. While discussion was modest, SNY plans a more direct patient focus in second half, the analyst comments.
Butt said while while they would have appreciated greater focus, given investments and plans for second half, SNY appears committed to Afrezza for now. He said what matters still is: 1) the growth trajectory in prescriptions 2) hurdles getting worked out, 3) whether... More
